Transthyretin Amyloid Cardiomyopathy Latest Advances

Find the Latest Research About Transthyretin Amyloid Cardiomyopathy

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 773 publications

Temporal Trends in Incidence and Prevalence of Transthyretin Amyloid Cardiomyopathy in the United States.

Temporal Trends in Incidence and Prevalence of Transthyretin Amyloid Cardiomyopathy in the United States.

Journal: Journal of the American Heart Association
Published: June 23, 2026

Development of Human iPSC-based Microphysiogical Models of Transthyretin Amyloid Cardiomyopathy.

Development of Human iPSC-based Microphysiogical Models of Transthyretin Amyloid Cardiomyopathy.

Journal: Research square
Published: June 22, 2026

Correction to: Long-Term Efficacy of Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy by National Amyloidosis Centre stage.

Correction to: Long-Term Efficacy of Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy by National Amyloidosis Centre stage.

Journal: European journal of heart failure
Published: June 17, 2026

First Japanese Case of Hereditary Transthyretin Amyloid Cardiomyopathy with an Ile68Leu Variant: A Case Report.

First Japanese Case of Hereditary Transthyretin Amyloid Cardiomyopathy with an Ile68Leu Variant: A Case Report.

Journal: Internal medicine (Tokyo, Japan)
Published: June 10, 2026

Diagnostic Trends and Geographic Health Care Disparities Among Patients With Transthyretin Amyloid Cardiomyopathy.

Diagnostic Trends and Geographic Health Care Disparities Among Patients With Transthyretin Amyloid Cardiomyopathy.

Journal: Journal of the American Heart Association
Published: June 09, 2026

Response to the letter to the editor regarding "Use of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography in monitoring therapeutic changes of RNA interference therapeutics in patients with hereditary transthyretin amyloid cardiomyopathy".

Response to the letter to the editor regarding "Use of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography in monitoring therapeutic changes of RNA interference therapeutics in patients with hereditary transthyretin amyloid cardiomyopathy".

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: June 05, 2026

Relevant Adverse Events and Drug Discontinuation of Sacubitril/Valsartan in Patients with Transthyretin Amyloid Cardiomyopathy - Insights from the REVIEW-HF Registry.

Relevant Adverse Events and Drug Discontinuation of Sacubitril/Valsartan in Patients with Transthyretin Amyloid Cardiomyopathy - Insights from the REVIEW-HF Registry.

Journal: International heart journal
Published: May 17, 2026

Clinical Implications of Myocardial T1 Mapping Parameters in Relation to Left Ventricular Characteristics in Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy.

Clinical Implications of Myocardial T1 Mapping Parameters in Relation to Left Ventricular Characteristics in Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy.

Journal: International heart journal
Published: May 17, 2026

Comment on "Use of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography in monitoring therapeutic changes of RNA interference therapeutics in patients with hereditary transthyretin amyloid cardiomyopathy".

Comment on "Use of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography in monitoring therapeutic changes of RNA interference therapeutics in patients with hereditary transthyretin amyloid cardiomyopathy".

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: May 14, 2026

Pathogenic Characterization of a Novel G47R Transthyretin Mutation in Early-Onset Amyloid Cardiomyopathy.

Pathogenic Characterization of a Novel G47R Transthyretin Mutation in Early-Onset Amyloid Cardiomyopathy.

Journal: Journal of the American Heart Association
Published: May 14, 2026

Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy.

Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy.

Journal: Circulation. Heart failure
Published: May 09, 2026

Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy With and Without Atrial Fibrillation: Results From ATTRibute-CM.

Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy With and Without Atrial Fibrillation: Results From ATTRibute-CM.

Journal: Journal of cardiac failure
Published: May 08, 2026
Showing 1-12 of 773

Last Updated: 06/30/2026